New insights for development of a safe and protective RSV vaccine

Human Vaccines

Volumn 6, Issue 6, 2010, Pages 482-492

  Blanco, Jorge C G ^a   Boukhvalova, Marina S ^a   Shirey, Kari Ann ^b   Prince, Gregory A ^a   Vogel, Stefanie N ^b  

^a Virion Systems Inc   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Rsv vaccine; TLR 4; Vaccine enhancement of disease

Indexed keywords

CYTOKINE; LOT 100; LOT 100 VACCINE; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

CELL ACTIVATION; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION PREVENTION; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; NOTE; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TREATMENT FAILURE;

EID: 77956685320     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.6.11562     Document Type: Note

References (128)

1. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003; 143:22-5.
2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. Jama 1999; 282:1440-6.
3. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001; 183:16-22.
4. Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum Vaccin 2009; 5:582-91.
5. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999; 179:25-30. (Pubitemid 29028334)
6. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-59. (Pubitemid 40570923)
7. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371-84.
8. Harrington RD, Hooton TM, Hackman RC, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992; 165:987-93.
9. Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997; 102:27-30. (Pubitemid 27203566)
10. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory syncytial virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979; 300:530-4.
11. Collins PL, Crowe JE. Respiratory syncytial virus and metapneumovirus. In: Knipe DM, Howley PM, ed. Field virology. Vol. 2. Philadelphia: Lippincott- Williams & Wilkins 2007; 1601-46.
12. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B, Bjorksten B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995; 95:500-5.
13. The Prevent Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99:93-9.
14. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7.
15. American Association of Pediatrics (AAP). Summary of Recommendations of the AAP Committee on Infectious Diseases. AAP News 2002; 21:232-3.
16. Collins PL, Huang YT, Wertz GW. Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci USA 1984; 81:7683-7.
17. Karron RA, Buonagurio DA, Georgiu AF, et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci USA 1997; 94:13961-6.
18. Olmsted RA, Elango N, Prince GA, et al. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA 1986; 83:7462-6. (Pubitemid 16000542)
19. Pemberton RM, Cannon MJ, Openshaw PJ, Ball LA, Wertz GW, Askonas BA. Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J Gen Virol 1987; 68:2177-82.
20. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infet Dis 1997; 176:1215-24.
21. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989; 63:2941-50.
22. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969; 89:449-63.
23. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969; 89:435-48.
24. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21.
25. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34.
26. McIntosh K, Chanock RM. Respiratory syncytial virus. In: Fields BN, ed. Virology 1990; 38:1045-72.
27. Prince GA, Horswood RL, Camargo E, Koenig D, Chanock RM. Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun 1983; 42:81-7. (Pubitemid 13012438)
28. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985; 55:517-20.
29. Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother 1987; 31:1882-6. (Pubitemid 18009554)
30. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42.
31. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-104.
32. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998; 177:467-9.
33. Prince GA, Mond JJ, Porter DD, Yim KC, Lan SJ, Klinman DM. Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 2003; 77:13156-60.
34. Piedra PA, Cron SG, Jewell A, et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 2003; 21:2448-60.
35. Prince GA, Capiau C, Deschamps M, et al. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. J Virol 2000; 74:10287-92.
36. Du RP, Jackson GE, Wyde PR, et al. A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3. Biotechnology (NY) 1994; 12:813-8.
37. Li X, Sambhara S, Li CX, et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 2000; 269:54-65. (Pubitemid 30183169)
38. Bembridge GP, Rodriguez N, Garcia-Beato R, Nicolson C, Melero JA, Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 2000; 81:2519-23.
39. Park EK, Soh BY, Jang YS, Park JH, Chung GH. Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus. Mol Cells 2001; 12:50-6.
40. Vaughan K, Rhodes GH, Gershwin LJ. DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 2005; 23:2928-42. (Pubitemid 40386495)
41. Wu H, Dennis VA, Pillai SR, Singh SR. RSV fusion (F) protein DNA vaccine provides partial protection against viral infection. Virus Res 2009; 145:39-47.
42. Dagouassat N, Robillard V, Haeuw JF, et al. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. Vaccine 2001; 19:4143-52. (Pubitemid 32703634)
43. Murawski MR, Bowen GN, Cerny AM, et al. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 2009; 83:1492-500.
44. de Waal L, Power UF, Yuksel S, et al. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine 2004; 22:915-22. (Pubitemid 38221085)
45. Zhang Y, Luxon BA, Casola A, Garofalo RP, Jamaluddin M, Brasier AR. Expression of Respiratory Syncytial Virus-Induced Chemokine Gene Networks in Lower Airway Epithelial Cells Revealed by cDNA Microarrays. J Virol 2001; 75:9044-58. (Pubitemid 32851909)
46. Dreizin RS, Vyshnevetskaia LO, Bagdamian EE, Iankevich OD, Tarasova LB. Experimental RS virus infection of cotton rats. A viral and immunofluorescent study. Vopr Virusol 1971; 16:670-6.
47. Prince GA, Horswood RL, Berndt J, Suffin SC, Chanock RM. Respiratory syncytial virus infection in inbred mice. Infect Immun 1979; 26:764-6.
48. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 1978; 93:771-91.
49. Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophilaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985; 3:193-206. (Pubitemid 16225057)
50. Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999; 18:223-31.
51. Prince GA, Jenson AB, Hemming VG, et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol 1986; 57:721-8.
52. Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJ. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J Immunol 1998; 161:6215-22. (Pubitemid 28535994)
53. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1:398-401.
54. van Schaik SM, Obot N, Enhorning G, et al. Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice. J Med Virol 2000; 62:257-66.
55. Durbin JE, Johnson TR, Durbin RK, et al. The role of IFN in respiratory syncytial virus pathogenesis. J Immunol 2002; 168:2944-52.
56. Johnson TR, Mertz SE, Gitiban N, et al. Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol 2005; 174:7234-41. (Pubitemid 40705692)
57. Zhou W, Hashimoto K, Moore ML, et al. IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. Microbes Infect 2006; 8:2880-9.
58. Shirey KA, Pletneva L, Puche A, et al. Control of RSV-induced lung injury by alternatively activated Macrophages is IL-4Rα-, TLR4- and IFNβ-dependent. Mucosal Imm In Press.
59. Durbin JE, Durbin RK. Respiratory syncytial virus-induced immunoprotection and immunopathology. Viral Immunol 2004; 17:370-80.
60. Prince GA, Prieels JP, Slaoui M, Porter DD. Pulmonary lesions in primary respiratory syncytial virus infection, reinfection and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus). Lab Invest 1999; 79:1385-92.
61. Prince GA, Curtis SJ, Yim KC, Porter DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001; 82:2881-8.
62. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 1998; 72:2871-80.
63. Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med 1998; 188:1967-72. (Pubitemid 28536783)
64. Baldridge JR, Crane RT. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999; 19:103-7.
65. Kakuk TJ, Soike K, Brideau RJ, et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 1993; 167:553-61. (Pubitemid 23056319)
66. Gershwin LJ, Schelegle ES, Gunther RA, et al. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. Vaccine 1998; 16:1225-36.
67. + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J Virol 1992; 66:1277-81.
68. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151:2032-40. (Pubitemid 23235675)
69. Sparer TE, Matthews S, Hussell T, et al. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 1998; 187:1921-6. (Pubitemid 28262454)
70. Roman M, Calhoun WJ, Hinton KL, et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Crit Care Med 1997; 156:190-5. (Pubitemid 27293187)
71. Bont L, Heijnen CJ, Kavelaars A, et al. Local interferon- gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 2001; 184:355-8. (Pubitemid 32662184)
72. Chen ZM, Mao JH, Du LZ, Tang YM. Association of cytokine responses with disease severity in infants with respiratory syncytial virus infection. Acta Paediatr 2002; 91:914-22.
73. Tripp RA, Moore D, Barskey At, et al. Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. J Infect Dis 2002; 185:1388-94. (Pubitemid 34507959)
74. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003; 168:633-9.
75. Semple MG, Dankert HM, Ebrahimi B, et al. Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P. PLoS One 2007; 2:1038.
76. Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007; 195:1126-36.
77. Byeon JH, Lee JC, Choi IS, Yoo Y, Park SH, Choung JT. Comparison of cytokine responses in nasopharyngeal aspirates from children with viral lower respiratory tract infections. Acta Paediatr 2009; 98:725-30.
78. Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein- 1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 2001; 184:393-9. (Pubitemid 32718501)
79. Brandenburg AH, Kleinjan A, van Het Land B, et al. Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity. J Med Virol 2000; 62:267-77.
80. Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine 2006; 24:5027-35. (Pubitemid 43782692)
81. Blanco JC, Boukhvalova M, Pletneva L, Prince GA, Vogel SN. Re-thinking Respiratory Syncytial Virus vaccines. Recent Res Devel Experimental Med 2004; 1:75-94.
82. Zhou Y, McLane M, Levitt RC. Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir Res 2001; 2:80-4.
83. Dodd JS, Lum E, Goulding J, Muir R, Van Snick J, Openshaw PJ. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol 2009; 183:7006-13.
84. Yim KC, Cragin RP, Boukhvalova MS, et al. Human metapneumovirus: Enhanced pulmonary disease in cotton rats immunized with formalin-inactivated virus vaccine and challenged. Vaccine 2007; 25:5034-40.
85. Haziot A, Ferrero E, Kontgen F, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4:407-14. (Pubitemid 26174055)
86. Perera PY, Vogel SN, Detore GR, Haziot A, Goyert SM. CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. J Immunol 1997; 158:4422-9. (Pubitemid 127483946)
87. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511.
88. Poltorak A, Smirnova I, He X, et al. Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 1998; 24:340-55.
89. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-8.
90. Qureshi ST, Lariviere L, Leveque G, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999; 189:615-25. (Pubitemid 29193362)
91. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675-80.
92. Perera PY, Mayadas TN, Takeuchi O, et al. CD11b/ CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression. J Immunol 2001; 166:574-81.
93. Shimazu R, Akashi S, Ogata H, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777-82. (Pubitemid 29272694)
94. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN. MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001; 276:38044-51.
95. Gioannini TL, Teghanemt A, Zhang D, et al. Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA 2004; 101:4186-91. (Pubitemid 38405904)
96. Kim HM, Park BS, Kim JI, et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 2007; 130:906-17.
97. Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007; 316:1632-4. (Pubitemid 46982039)
98. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458:1191-5.
99. Toshchakov V, Jones BW, Perera PY, et al. TLR4, but not TLR2, mediates IFNbeta-induced STAT1alpha/ beta-dependent gene expression in macrophages. Nat Immunol 2002; 3:392-8.
100. Gao JJ, Diesl V, Wittmann T, et al. Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J Leukoc Biol 2002; 72:1234-45. (Pubitemid 36008895)
101. Ohmori Y, Hamilton TA. Requirement for STAT1 in LPS-induced gene expression in macrophages. J Leukoc Biol 2001; 69:598-604. (Pubitemid 32294845)
102. Vogel SN, Fitzgerald KA, Fenton MJ. TLRs: differential adapter utilization by toll-like receptors mediates TLR-specific patterns of gene expression. Mol Interv 2003; 3:466-77.
103. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001; 75:10730-7.
104. Rallabhandi P, Bell J, Boukhvalova MS, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure and signaling. J Immunol 2006; 177:322-32. (Pubitemid 43939144)
105. Haeberle HA, Takizawa R, Casola A, et al. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis 2002; 186:1199-206. (Pubitemid 35192997)
106. Schlender J, Hornung V, Finke S, et al. Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol 2005; 79:5507-15. (Pubitemid 40548219)
107. Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 2005; 79:3350-7. (Pubitemid 40327923)
108. Liu P, Jamaluddin M, Li K, Garofalo RP, Casola A, Brasier AR. Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. J Virol 2007; 81:1401-11. (Pubitemid 46167861)
109. Ehl S, Bischoff R, Ostler T, et al. The role of Toll-like receptor 4 versus interleukin-12 in immunity to respiratory syncytial virus. Eur J Immunol 2004; 34:1146-53. (Pubitemid 39255994)
110. Mandelberg A, Tal G, Naugolny L, et al. Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncitial virus bronchiolitis. Clin Exp Immunol 2006; 144:48-52.
111. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-91. (Pubitemid 30394990)
112. Awomoyi AA, Rallabhandi P, Pollin TI, et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 2007; 179:3171-7.
113. Tal G, Mandelberg A, Dalal I, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004; 189:2057-63.
114. Groskreutz DJ, Monick MM, Yarovinsky TO, et al. Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells. J Immunol 2007; 179:2741-7.
115. Boukhvalova MS, Sotomayor TB, Point RC, Pletneva LM, Prince GA, Blanco JC. Activation of Interferon Response Through Toll-Like Receptor 3 Impacts Viral Pathogenesis and Pulmonary Toll-Like Receptor Expression During Respiratory Syncytial Virus and Influenza Infections in the Cotton Rat Sigmodon hispidus Model. J Interferon Cytokine Res 2009.
116. Sabbah A, Chang TH, Harnack R, et al. Activation of innate immune antiviral responses by Nod2. Nat Immun 2009; 10:1073-80.
117. Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006; 12:905-7. (Pubitemid 44175141)
118. Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982; 257:11808-15. (Pubitemid 13218648)
119. Alderson MR, McGowan P, Baldridge JR, Probst P. TLR4 agonists as immunomodulatory agents. J Endotoxin Res 2006; 12:313-9.
120. Salkowski CA, Detore GR, Vogel SN. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon and interleukin-10 mRNA production in murine macrophages. Infect Immun 1997; 65:3239-47.
121. Prince GA, Denamur F, Deschamps M, et al. Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 2001; 19:2048-54. (Pubitemid 32178354)
122. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15:34-41.
123. Shaw CA, Otten G, Wack A, et al. Antibody affinity maturation and respiratory syncytial virus disease. Nat Med 2009; 15:725.
124. Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002; 196:859-65.
125. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 1999; 163:3771-7. (Pubitemid 29450901)
126. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
127. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connection maps. Science 2003; 300:1527-8.
128. Richardson JY, Ottolini MG, Pletneva L, et al. Respiratory syncytial virus (RSV) infection induces cyclooxygenase 2: a potential target for RSV therapy. J Immunol 2005; 174:4356-64. (Pubitemid 40396018)